Guangdong Raynovent Biotech Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Other

Guangdong Xianqiang Pharmaceutical Co., Ltd

Zhuowei Liu

Chaofeng Long

Xiaoxin Chen

Shuhui Chen

Jian Li

Peng Zhang

Fang Liu

Lingyun Wu

Zhengxia Chen

Xing Liu

Lijuan Chen

Guoping Hu

Zhiqiang Liu

Cheng Xie

Meibi Dai

Chengwu Liu

Li Zhang

Hao Wu

Peng Li

Zheng Wang

Kevin X Chen

Jian Xiong

Jun Lin

Changqing Wei

Jingjing Wang

Zhifei Fu

Guibai Liang

Jian Wei Li

Zhengwei Li

Yikai Wang

Haixia Zhao

Yunhui Li

Yang Zhang

Zhenyou Tan

Zhiwei Cheng

Jiajun Huang

Guangqiang Zhou

Linyun Wu

Haoyu Ye

Chenshi Xie

Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.

Dominant salt forms of pyrimidine derivatives, and crystal forms thereof

Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.

Crystal form and salt form of pyridoimidazole compound and preparation method therefor

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof. 

Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-&#x3b1; inhibitors.

Hydroxyl purine compounds and applications thereof

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases. 

FGFR4 inhibitor and preparation method and use thereof

Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor. 

Crystal form and salt form of and preparation method for tyrosine kinase inhibitor

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II): 

Tyrosine kinase inhibitor and pharmaceutical composition comprising same

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF&#x3b1; inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof. 

Hydroxyl purine compounds and use thereof

A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.  In Formula I, the variables are as described herein.

Histone deacetylase inhibitor, and preparation method and use thereof

The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-&#x3b1; inhibitor. 

Crystal form A of 7-(cyclopropylmethyl)-1-((()-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF&#x3b1; inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof. 

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Quinoline derivatives as SMO inhibitors

Growing community of inventors

Dongguan, China

Zhuowei Liu